Golimumab-Associated Glomerulonephritis
- PMID: 33369915
- DOI: 10.1097/MJT.0000000000000946
Golimumab-Associated Glomerulonephritis
Conflict of interest statement
The authors have no conflicts of interest to declare.
References
-
- Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239–245.
-
- Keystone EC, Genovese MC, Klareskog L, et al. Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis. 2009;68:789–796.
-
- Keystone EC, Genovese MC, Hall S, et al. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: results through 2 years of the GO-FORWARD study extension. J Rheumatol. 2013;40:1097–1103.
-
- Saka Y, Taniguchi Y, Nagahara Y, et al. Rapidly progressive lupus nephritis associated with golimumab in a patient with systemic lupus erythematosus and rheumatoid arthritis. Lupus. 2017;26:447–448.
-
- Pàmies A, Castro S, Poveda MJ, et al. Leucocytoclastic vasculitis associated with golimumab. Rheumatology (Oxford). 2013;52:1921–1923.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources